Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-DZHK20)
The BioVAT-HF-DZHK20 trial is investigating under which conditions engineered human myocardium is safe to use in the treatment of patients with end-stage heart failure, a condition known as terminal heart failure (NYHA III or IV). To do so, engineered human myocardium will be implanted onto the heart muscle by means of a minimally invasive thoracotomy, a surgical opening of the thorax through an incision between two ribs, or open-heart surgery. With this study, the scientists hope to gain new insights into whether this intervention leads to better heart function, what dosage is the correct one and where the implantation of the artificial heart tissue is most effective.
Publications
Engineered heart muscle allografts for heart repair in primates and humans. Jebran, AF., Seidler, T., Tiburcy, M. et al. Nature. 2025 Jan 29. doi: 10.1038/s41586-024-08463-0.
Principal Investigators
Principal investigator: Wolfram-Hubertus Zimmermann (Göttingen)
Press releases and news
Study recruitment is available in these cities
The map only displays recruitment locations within Germany.
Study information
BioVAT-HF-DZHK20
- Recruiting status
- Recruiting ongoing
- Recruitment start
- 02.2021
- Patients
-
53
- Clinical Trials Registrierung
- Category
- Early clinical study
- DZHK Funding
- € 1.185.447
- Links
- https://biovat.dzhk.de
-
Operative contact
Main study center
Florian Walker, MD
biovat.info@med.uni-goettingen.de